Ingevity (NGVT) stock has been in focus after recent trading performance, prompting investors to reassess how the company’s materials and specialty chemicals portfolio lines up with its current valuation and recent share price moves.

At a share price of $73.41, Ingevity has seen a 12.90% 1 month share price return and a 22.17% year to date share price return, while its 1 year total shareholder return of 77.40% points to momentum that has been building rather than fading.

If recent gains in Ingevity have you reassessing opportunities in materials and related sectors, it could be a good moment to scan 8 top copper producer stocks.

With Ingevity trading at $73.41 and data pointing to both an intrinsic discount and a gap to analyst price targets, the key question is whether the recent rally leaves value on the table or if the market is already pricing in future growth.

Most Popular Narrative: 14.1% Undervalued

On the most followed narrative, Ingevity stock at $73.41 sits below an assessed fair value of $85.50, with the gap tied directly to expectations about future profitability and capital allocation rather than current losses.

Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Want to see why a company reporting a $156.0 million loss today is still tied to a higher fair value? The core of this narrative is a sharp swing in margins, earnings power and future valuation multiples that depends on a leaner portfolio and active buybacks. Curious which exact assumptions need to hold for that to stack up?

Result: Fair Value of $85.50 (UNDERVALUED)

However, the Ingevity narrative also hinges on APT margins stabilising and portfolio reshaping going to plan, so prolonged tariff pressure or weaker industrial demand could quickly test those assumptions.

Another View: What Multiples Say About Ingevity Stock

While the narrative-based fair value suggests Ingevity stock could have upside, the P/S ratio tells a more cautious story. At 2.2x sales, Ingevity trades well above both the US Chemicals industry average of 1.1x and a fair ratio of 1.4x. This implies valuation risk if sentiment cools.

For investors, that gap means paying a richer price for each dollar of current revenue than both peers and what the fair ratio implies the market could move toward. It is worth asking which signal you trust more and why.

Next Steps

Seen enough to form a first impression of Ingevity, but still unsure how the risk and reward balance really looks for you personally? Take a closer look at the detailed breakdown of 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Ingevity?

If Ingevity has sharpened your perspective, do not stop here. Broaden your watchlist with other opportunities that match different income, value and risk profiles.

• Target higher yield potential while keeping an eye on resilience by reviewing 8 dividend fortresses.
• Hunt for quality at a sensible price by scanning the 45 high quality undervalued stocks that currently fit strict fundamentals filters.
• Spot opportunities others may be missing by checking the screener containing 20 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.